Next 10 |
Treatment with AFM28 innate cell engager (ICE®), designed to target CD123-positive cancer cells in patients with acute myeloid leukemia (AML), led to dose-dependent tumor growth control in a validated in vivo mouse model AFM28 led to an effective reduction of CD123-expressing AML patie...
The preliminary results from the phase 2 study investigating AFM24 in combination with the checkpoint inhibitor atezolizumab in patients with EGFR wild-type non-small cell lung cancer have been accepted for poster presentation MANNHEIM, Germany, April 24, 2024 (GLOBE NEWSWIRE) -- Affimed N....
2024-03-28 12:04:42 ET Affimed N.V. (AFMD) Q4 2023 Earnings Conference Call March 28, 2024 8:30 AM ET Company Participants Alexander Fudukidis – Head-Investor Relations Andreas Harstrick – Chief Medical Officer and Interim Acting Chief Executive Officer...
Swire Pacific Ltd. ADR (Class A) (SWRAY) is expected to report for Q4 2023 Troika Media Group Inc. (TRKAQ) is expected to report for quarter end 2023-12-31 American Environmental Partners Inc. (AEPT) is expected to report for quarter end 2023-12-31 Veolia Environnement S.A. ADR (VEOEY...
2024-03-28 06:36:57 ET More on Affimed Affimed falls on 1-for-10 reverse stock split Affimed CEO Adi Hoess to step down, Andreas Harstrick appointed interim CEO Seeking Alpha’s Quant Rating on Affimed Historical earnings data for Affimed Financ...
AFM24 combination with atezolizumab (AFM24-102): Follow-up of the Phase 1/2a combination study confirmed four responses in the non-small cell cancer (NSCLC) EGFR -wildtype cohort: one complete response (CR), three partial responses (PR), and seven stable disease patients in the 15 heavily p...
MANNHEIM, Germany, March 21, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release full ye...
2024-03-14 10:00:17 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming Waters, Moderna most shorted ...
2024-03-11 09:02:02 ET Affimed N.V. (AFMD) announced stock split at a ratio of 1-for-10 on 2024-03-11 ... Full story available on KlickAnalytics.com
2024-03-08 09:43:32 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Astra Space (NASDAQ: ASTR ) stock is in the news Friday after the U.S. space travel company revealed plans to go private . Astra Space is being taken private by a new parent...
News, Short Squeeze, Breakout and More Instantly...
Affimed N.V. Company Name:
AFMD Stock Symbol:
NASDAQ Market:
Treatment with AFM28 innate cell engager (ICE®), designed to target CD123-positive cancer cells in patients with acute myeloid leukemia (AML...
Treatment with AFM28 innate cell engager (ICE®), designed to target CD123-positive cancer cells in patients with acute myeloid leukemia (AML), led to dose-dependent tumor growth control in a validated in vivo mouse model AFM28 led to an effective reduction of CD123-expressing AML patie...
The preliminary results from the phase 2 study investigating AFM24 in combination with the checkpoint inhibitor atezolizumab in patients with EGFR wild-type non-small cell lung cancer have been accepted for poster presentation MANNHEIM, Germany, April 24, 2024 (GLOBE NEWSWIRE) -- Affimed N....